Internal Medicine Research and Non-Research Awards – First Quarter 2018

From 01/01/2018- To 03/31/2018,

Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost

 

Burdorf, Adam F

Investigation to optimize hemodynamic management of heartmate II left ventricular assist device patients using the CardioMEMS pulmonary artery pressure sensor in advanced hart failure, 21370, St. Jude Medical Business Services, Inc., 01/18/18-01/17/20, $24,952 , $5,708 , $30,660

 

Desouza, Cyrus Victor

Continuation of Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), 15785, George Washington University, 09/06/17-07/31/18, $577,815 , $267,435 , $845,250

Midwestern Collaborative for Treating Obesity in Rural Primary Care, 18181, University of Kansas Medical Center Research Institute Inc, 01/01/18-12/31/18, $123,260 , $43,509 , $166,769

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis., 21324, Novo Nordisk Pharmaceuticals, Inc., 01/17/18-01/16/20, $0 , $16,737 , $16,737

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis., 21324, Novo Nordisk Pharmaceuticals, Inc., 01/17/18-01/16/20, $86,829 , $5,579 , $92,408

 

Shivaswamy, Vijay

ICA William Taylor-Prominent study at VA, 21807, Nebraska Educational Biomedical Research Association, 04/01/18-06/30/19, $20,636 , $0 , $20,636

ICA Ramesh Ramalingam-Prominent study at VA, 21806, Nebraska Educational Biomedical Research Association, 04/01/18-06/30/19, $56,247 , $0 , $56,247

 

Thomes, Paul G

Role of LipidDroplet Ubiquitylation in Hepatic Manifestation of Metabolic Syndrome, 21610, University of Nebraska – Lincoln, 12/08/17-05/31/18, $42,685 , $0 , $42,685

 

Bonasera, Stephen John

Live Well: A Mobile Intervention for Bipolar Disorder, 20614, Northwestern University-Chicago, 07/01/17-06/30/18, $1,861 , $940 , $2,801

The Care Ecosystem: Navigating Patients and Caregivers Through Stages of Dementia Care, 21403, University of California – San Francisco, 09/30/17-05/31/18, $79,112 , $40,743 , $119,855

 

Florescu, Diana Florentina

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection, 21381, Emergent BioSolutions Canada Inc., 01/03/17-01/02/20, $0 , $7,736 , $7,736

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection, 21381, Emergent BioSolutions Canada Inc., 01/03/18-01/02/20, $50,172 , $2,579 , $52,751

A Phase III, Randomized, Double-Blinde, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients, 21422, Merck Sharp & Dohme Corp., 03/23/18-03/22/20, $0 , $36,398 , $36,398

A Phase III, Randomized, Double-Blinde, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients, 21422, Merck Sharp & Dohme Corp., 03/23/18-03/22/20, $189,654 , $12,132 , $201,786

 

Kalil, Andre C

Rapid Assessment of Acute Illness and Injury to Enhance the U.S. Response to Public Health Emergencies, 21720, University of Southern California, 08/01/17-07/31/18, $9,435 , $4,859 , $14,294

(ARLG) Antibacterial Resistance Leadership Group: Achaogen Lung PK, 20336, Duke University, 12/01/17-11/30/18, $22,664 , $11,672 , $34,336

 

Rupp, Mark E

NEBRASKA ANTIMICROBIAL STEWARDSHIP ASSESSMENT AND PROMOTION (NEBRASKA ASAP) SUBAWARD, 21053, NE DHHS, 08/01/17-07/31/18, $499,589 , $14,171 , $513,760

 

Swindells, Susan

National AIDS Education and Training Center Grants, 530, University of Illinois – Chicago, 07/01/17-06/30/18, $48,687 , $3,895 , $52,582

AIDS Clinical Trials Group Network (ACTG), 16481, Brigham & Women's Hospital, 12/01/17-11/30/18, $16,795 , $8,489 , $25,284

AIDS Clinical Trials Group (ACTG): Protocol Chair Support, 20097, Brigham & Women's Hospital, 12/01/17-11/30/18, $3,128 , $1,575 , $4,703

Title III:Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program), 6247, DHHS/HRSA, 01/01/18-12/31/18, $307,305 , $0 , $307,305

 

Vanschooneveld, Trevor Craig

Zerbaxa Medication Use Evaluation, 21321, Merck & Co, Inc., 01/30/18-01/29/20, $36,976 , $9,354 , $46,330

 

Baljevic, Muhamed

A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma, 21246, Amgen, Inc., 02/21/18-02/18/20, $0 , $26,224 , $26,224

A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma, 21246, Amgen, Inc., 02/21/18-02/18/20, $137,484 , $8,742 , $146,226

 

Bhatt, Vijaya R

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3-ITD AML, 21280, National Marrow Donor Program, 12/19/17-12/18/18, $82,729 , $20,730 , $103,459

 

Grem, Jean Linette

An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002, 21526, Hoosier Oncology Group, LLC, 01/26/18-01/25/19, $29,572 , $7,429 , $37,001

Gundabolu, Krishna

A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with PrimaryMyelofibrosis (PMF), Post-Polycythemia Vera MF (post- PV MF), and Post-Essential Thrombocythemia MF (post- ET MF), 21450, Samus Therapeutics, Inc., 03/12/18-03/11/20, $0 , $63,295 , $63,295

A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with PrimaryMyelofibrosis (PMF), Post-Polycythemia Vera MF (post- PV MF), and Post-Essential Thrombocythemia MF (post- ET MF), 21450, Samus Therapeutics, Inc., 03/12/18-03/11/20, $327,591 , $21,099 , $348,690

 

Lunning, Matthew A

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Non Hodgkin Lymphoma, 21385, Curis, Inc., 12/19/17-12/18/19, $0 , $57,676 , $57,676

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Non Hodgkin Lymphoma, 21385, Curis, Inc., 12/19/17-12/18/19, $298,772 , $19,225 , $317,997

 

Teply, Benjamin Addison

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis, 21405, Johns Hopkins University, 01/16/18-01/15/20, $0 , $14,236 , $14,236

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis, 21405, Johns Hopkins University, 01/16/18-01/15/20, $76,005 , $4,745 , $80,750

 

Murphy, P. James  

A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System, 20461, Cincinnati Children's Hospital Medical Center, 01/01/18-12/31/18, $30,000 , $2,400 , $32,400

A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics, 21339, Proteostasis Therapeutics, Inc., 01/01/18-12/31/20, $0 , $9,746 , $9,746

A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics, 21339, Proteostasis Therapeutics, Inc., 01/01/18-12/31/20, $52,979 , $3,249 , $56,228

 

Poole, Jill Adair

Role of Pattern Recognition Receptors in Organic Dust-induced Airway Inflammation, 14123, DHHS/NIH/NIEHS, 01/01/18-12/31/18, $287,070 , $144,970 , $432,040

 

Rennard, Stephen Israel

Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC), 19461, University of Pittsburgh, 08/01/17-07/31/18, $6,839 , $3,454 , $10,293

RofLumilast orAzithromycin to prevent COPD Exacerbations (RELIANCE) Study, 19378, University of Illinois – Chicago, 11/29/17-12/15/18, $12,330 , $4,932 , $17,262

 

Thompson, Austin Bassett

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD), 20845, Boehringer Ingelheim Pharmaceuticals, Inc., 01/01/18-12/31/20, $0 , $13,181 , $13,181

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD), 20845, Boehringer Ingelheim Pharmaceuticals, Inc., 01/01/18-12/31/20, $70,596 , $4,394 , $74,990

A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts, 21200, Actelion Pharmaceuticals Ltd., 02/09/18-11/30/19, $0 , $13,309 , $13,309

A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts, 21200, Actelion Pharmaceuticals Ltd., 02/09/18-11/30/19, $71,250 , $4,436 , $75,686